Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma.

@article{Richardson2009SafetyAE,
  title={Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma.},
  author={Paul G Richardson and Sundar Jagannath and Mohamed A. Hussein and James R Berenson and Seema B. Singhal and David Irwin and Stephanie F. Williams and William Ira Bensinger and Ashraf Badros and Robert A. Vescio and Laurie Kenvin and Zhinuan Yu and Marta Olesnyckyj and Jerome B. Zeldis and Robert Knight and Kenneth C. Anderson},
  journal={Blood},
  year={2009},
  volume={114 4},
  pages={772-8}
}
Lenalidomide plus dexamethasone is effective for the treatment of relapsed and refractory multiple myeloma (MM); however, toxicities from dexamethasone can be dose limiting. We evaluated the efficacy and safety of lenalidomide monotherapy in patients with relapsed and refractory MM. Patients (N = 222) received lenalidomide 30 mg/day once daily (days 1-21 every 28 days) until disease progression or intolerance. Response, progression-free survival (PFS), overall survival (OS), time to progression… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 68 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 30 references

Lenalidomide, bortezomib, and dexamethasone (Rev/ Vel/Dex) in patients with relapsed or relapsed/ refractory multiple myeloma (MM): preliminary results of a phase II study [abstract

  • P Richardson, S Jagannath, N Raje
  • RICHARDSON et al BLOOD,
  • 2009
2 Excerpts

Phase II study of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with relapsed or relapsed and refractory multiple myeloma (MM) [abstract

  • KC Anderson, S Jagannath, A Jakubowiak
  • J Clin Oncol
  • 2008
1 Excerpt

proved survival in multiple myeloma and the impact of novel therapies

  • FE Davies, N Raje, T Hideshima
  • Blood
  • 2008

Similar Papers

Loading similar papers…